| Demographics |
| Female sex |
40 (62.5) |
| Median age, y (IQR) |
48.0 (44.8–60.0) |
Asian origin
|
59 (92.2)
|
Other autoimmune diseases
|
7/27 (25.9)
|
| Etiologic agents |
|
Mycobaterium avium
|
23 (40.4) |
|
M. abscessus
|
18 (31.6) |
|
M. fortuitum
|
7 (12.3) |
M. tuberculosis
|
6 (10.5)
|
| Other opportunistic infections |
39/52 (75.0) |
|
Herpesviridae reactivations |
23/52 (44.2) |
Salmonella spp.
|
13/52 (25.0)
|
| Median duration of intensive-phase therapy, mo (IQR) |
31.0 (22.8–60.0) |
| ≥6 |
31/31 (100) |
| ≥12 |
29/31 (93.5) |
| ≥18 |
27/31 (87.1) |
≥24
|
23/31 (74.2)
|
Long-term antimicrobial suppressive therapy
|
3/30 (10.0)
|
| Immunomodulatory therapies |
10/30 (33.3) |
| Rituximab |
6/30 (20.0) |
| IFN-γ |
5/30 (16.7) |
| Intravenous immunoglobulins |
2/30 (6.7) |
| Plasmapheresis |
2/30 (6.7) |
Cyclophosphamid
|
1/30 (3.3)
|
| Outcome |
| Cure |
21/62 (33.9) |
| Improvement |
6/62 (9.7) |
| Relapse/persistence |
29/62 (46.8) |
Death
|
6/62 (9.7)
|
| *Values are no. (%) except as indicated. Only articles with sufficient detail were analyzed. A complete listing of articles reviewed from the literature is provided in the online Technical Appendix Table (http://wwwnc.cdc.gov/EID/article/22/6/15-1860-Techapp1.pdf). IQR, interquartile range; IFN-γ, interferon gamma.
†Denominators indicate number of case-patients for which category of data was available. |
